In this podcast, prof. dr. Maha Hussain explains the results of the primary analysis of the fase III IMvigor010 study. In this trial, patients with high-risk muscle-invasive urothelial carcinoma were, after surgical resection, randomized to atezolizumab, an anti-PD-L1 antibody, or observed. Listen now to hear prof. dr. Hussain elaborate on the results and implications of this study.
Top
